# A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

> **NCT02102490** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 132 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT02102490
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-10
- **Primary completion:** 2016-04-30
- **Final completion:** 2018-10-22
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2020-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02102490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02102490, "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02102490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*